Loading…
Cocrystal Pharma, Inc. is projected to rise to $1.03 by 2027, a +2% move from its current price of $1.01. COCP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.9854 | $1.01 | $1.03 | -0.05% |
| Jul 14 | $0.9751 | $1.01 | $1.04 | -0.10% |
| Jul 15 | $0.9671 | $1.01 | $1.05 | -0.14% |
| Jul 16 | $0.9604 | $1.01 | $1.06 | -0.19% |
| Jul 17 | $0.9545 | $1.01 | $1.06 | -0.24% |
| Jul 18 | $0.9491 | $1.01 | $1.07 | -0.29% |
| Jul 19 | $0.9441 | $1.01 | $1.07 | -0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9441 | $1.01 | $1.07 | -0.34% |
| Week 2 | $0.9163 | $1.00 | $1.10 | -0.67% |
| Week 3 | $0.8948 | $0.9998 | $1.12 | -1.01% |
| Week 4 | $0.8766 | $0.9965 | $1.13 | -1.34% |
| Week 5 | $0.8605 | $0.9931 | $1.15 | -1.67% |
| Week 6 | $0.846 | $0.9898 | $1.16 | -2.00% |
| Week 7 | $0.8326 | $0.9864 | $1.17 | -2.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cocrystal Pharma, Inc. is a biotechnology company focused on discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.
The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Cocrystal develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV.
The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc.
was headquartered in Bothell, Washington.
COCP is a biotechnology stock focused on antiviral drug development. It trades at $0.982 per share with a market cap of $13.54M and is ranked 5034 by market capitalization. The long-range price outlook shows a path from near-term stability to substantial gains, with multi-year forecasts that rise from a near-term baseline toward higher levels in 2030, 2040, and 2050.
The 2030 average price is projected at $1.30 with a 32.1% ROI, and the 2050 average price is projected at $3.75 with a 282% ROI, illustrating a bullish long-term trajectory. In the near term, forecasts for 2026–2029 show more modest moves, with 2026 at an average near the current price and 0% ROI, followed by gradual gains through 2029.
A major floor 15.8% below — a decisive break under it would weaken the trend.
The nearest floor, 5.9% below — buyers have tended to step in here.
The nearest ceiling, 11.9% above — a clean break opens room to run.
A major ceiling 55.4% above — clearing it would confirm fresh momentum.
Key COCP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COCP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.01 | Sell | $1.01 | Sell |
| MA 10 | $1.02 | Sell | $1.02 | Sell |
| MA 20 | $1.01 | Sell | $1.03 | Sell |
| MA 50 | $1.12 | Sell | $1.09 | Sell |
| MA 100 | $1.16 | Sell | $1.13 | Sell |
| MA 200 | $1.11 | Sell | $1.19 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.55 | Neutral |
| Stoch RSI (14) | 57.20 | Neutral |
| CCI (20) | -11.40 | Neutral |
| Williams %R (14) | -62.50 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -4.72 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 37.50 | Neutral |
| TRIX (15) | -0.43 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 37.90 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 0.99 | Buy |
| ADX (14) | 17.67 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is NEUTRAL. The RSI(14) is 40, and the stock trades near its 50-day and 200-day simple moving averages at $1.14 and $1.11 respectively. The current support is at $0.95 and resistance at $1.13. Over the last 30 days, the price has ranged from a low of $0.8336 to a high of $1.16.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.86 | $1.01 | $1.23 | 0% | Neutral | |
| $0.8311 | $1.03 | $1.35 | +2% | Neutral | |
| $0.8572 | $1.09 | $1.48 | +8% | Neutral | |
| $0.8404 | $1.09 | $1.52 | +8% | Neutral | |
| $1.02 | $1.35 | $1.92 | +34% | Bullish | |
| $1.13 | $1.52 | $2.20 | +51% | Bullish | |
| $1.07 | $1.46 | $2.16 | +45% | Bullish | |
| $1.13 | $1.56 | $2.33 | +54% | Bullish | |
| $1.11 | $1.55 | $2.36 | +54% | Bullish | |
| $1.10 | $1.57 | $2.42 | +55% | Bullish | |
| $1.52 | $2.28 | $3.72 | +126% | Bullish | |
| $2.41 | $4.00 | $7.08 | +296% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.86 | $1.01 | $1.19 | +0.00% |
| August 2026 | $0.8222 | $0.9676 | $1.17 | -4.19% |
| September 2026 | $0.8163 | $0.9666 | $1.18 | -0.11% |
| October 2026 | $0.834 | $0.9929 | $1.22 | +2.72% |
| November 2026 | $0.8272 | $0.9892 | $1.22 | -0.37% |
| December 2026 | $0.8206 | $0.9854 | $1.23 | -0.39% |
Click any year to see its month-by-month COCP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cocrystal Pharma, Inc.'s 2026 outlook centres on $1.01, within a $0.86 to $1.23 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, COCP could reach as high as $1.35, with a base case around $1.03 and support toward $0.8311 — roughly +2% from $1.01. A consolidation phase looks the most probable path here.
Expect COCP to range from $0.8572 to $1.48 through 2028. The $1.09 average target implies a +8% move from current prices. That is up +6% on the projected 2027 average. Price action looks broadly range-bound.
The COCP price prediction for 2029 points to an average of $1.09 (low $0.8404, high $1.52) — a potential gain of +8% on today's $1.01. A consolidation phase looks the most probable path here.
In 2030, COCP is projected to trade between $1.02 and $1.92, averaging $1.35 — a potential gain of +34% from today's $1.01. That is up +24% on the projected 2029 average. Momentum favours further upside here.
Cocrystal Pharma, Inc.'s 2031 outlook centres on $1.52, within a $1.13 to $2.20 range. That is up +12% on the projected 2030 average. That marks a +51% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, COCP could reach as high as $2.16, with a base case around $1.46 and support toward $1.07 — roughly +45% from $1.01. Momentum favours further upside here.
Expect COCP to range from $1.13 to $2.33 through 2033. The $1.56 average target implies a +54% move from current prices. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The COCP price prediction for 2034 points to an average of $1.55 (low $1.11, high $2.36) — a potential gain of +54% on today's $1.01. Momentum favours further upside here.
In 2035, COCP is projected to trade between $1.10 and $2.42, averaging $1.57 — a potential gain of +55% from today's $1.01. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cocrystal Pharma, Inc.'s 2040 outlook centres on $2.28, within a $1.52 to $3.72 range. That is up +45% on the projected 2035 average. That marks a +126% change versus current levels. Momentum favours further upside here.
By 2050, COCP could reach as high as $7.08, with a base case around $4.00 and support toward $2.41 — roughly +296% from $1.01. Buyers look set to stay in control over this stretch.
Investing $1,000 in COCP today (≈ 990.09901 COCP) could be worth
$3,961.18
+$2,961.18 (+296%) by 2050 · US Dollar
Based on the average projected COCP price of $4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COCPwould be worth at today's price.
$1,000 invested in COCP on Jul 10, 2025 (≈ 636.942654 COCP) would be worth
$643.31
-$356.69 (-35.7%) today · 0.64× · US Dollar
Based on a COCP entry price of $1.57 vs. today's $1.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.04 | $971.15 | -2.9% |
| 1 month ago | $1 | $1,010 | +1.0% |
| 3 months ago | $1.25 | $808 | -19.2% |
| 6 months ago | $1.11 | $909.91 | -9.0% |
| 1 year ago | $1.57 | $643.31 | -35.7% |
| All time (5.0y) ago | $13.32 | $75.83 | -92.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COCP forecast.
Our base-case forecast reaches $2.00 around 2040.
Implied market cap at $2.00: $27.57M
The multi-year forecast shows a progression from near-term stability to stronger upside in the 2030s and beyond. The 2026 forecast lists a min of $0.86, an average of $0.982, a max of $1.19, and a 0% ROI with NEUTRAL sentiment. The 2027–2029 window yields 2027 $0.999 (ROI 1.7%), 2028 $1.05 (ROI 6.6%), and 2029 $1.04 (ROI 6.3%), all with NEUTRAL sentiment.
Beginning in 2030, sentiment turns BULLISH with 2030 avg $1.30 (ROI 32.1%), 2031 avg $1.45 (ROI 48.1%), 2032 avg $1.40 (ROI 42.3%), 2033 avg $1.49 (ROI 51.3%), 2034 avg $1.47 (ROI 50.1%), and 2035 avg $1.49 (ROI 51.3%). By 2040, the average rises to $2.15 (ROI 118.9%), and by 2050 the average reaches $3.75 (ROI 282%), with bullish sentiment indicated for these later years. These are estimates and not guarantees, and the asset may experience volatility, including an annualized volatility around 50%.
Tap a question to reveal the answer.
The forecast shows an average price of $1.30 per share, with a range from $0.9764 to $1.85 and a 32.1% ROI; sentiment is bullish.
Near-term sentiment is NEUTRAL, with a current price of $0.982 and a market cap of $13.54M. The long-term forecasts point to bullish sentiment from 2030 onward, with ROIs up to 282% by 2050. These are estimates, not guarantees.
The 2050 forecast lists a maximum price of $6.70, so reaching around that level is within the forecast, though not guaranteed.
Current price is $0.982 and market cap is $13.54M.
The 30-day picture is NEUTRAL with RSI(14) at 40. The 50-day SMA is $1.14 and the 200-day SMA is $1.11. Support is $0.95 and resistance is $1.13; the 30-day range is $0.8336 to $1.16.
Cocrystal Pharma, Inc. Community Discussion
0Share your Cocrystal Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.